REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
REGENXBIO announced it will host a webcast on May 14, 2026, to discuss topline results from the pivotal trial of RGX-202 for Duchenne muscular dystrophy. The company also plans to report its first quarter 2026 financial results and operational highlights pre-market on the same day.
Key figures
- Drug Name
- RGX-202
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.